CTMX
Price:
$0.89
Market Cap:
$69.65M
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical tri...[Read more]
Industry
Biotechnology
IPO Date
2015-10-08
Stock Exchange
NASDAQ
Ticker
CTMX
According to CytomX Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -41.34%. This represents a change of 238.67% compared to the average of -12.21% of the last 4 quarters.
The mean historical ROE of CytomX Therapeutics, Inc. over the last ten years is -43.24%. The current -41.34% ROE has changed -4.40% with respect to the historical average. Over the past ten years (40 quarters), CTMX's ROE was at its highest in in the March 2015 quarter at 103.59%. The ROE was at its lowest in in the September 2022 quarter at -79.55%.
Average
-43.24%
Median
-63.15%
Minimum
-200.02%
Maximum
113.47%
Discovering the peaks and valleys of CytomX Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 209.44%
Maximum Annual ROE = 113.47%
Minimum Annual Increase = -225.75%
Minimum Annual ROE = -200.02%
Year | ROE | Change |
---|---|---|
2023 | 1.20% | -98.94% |
2022 | 113.47% | -225.75% |
2021 | -90.23% | 36.65% |
2020 | -66.03% | -66.99% |
2019 | -200.02% | 209.44% |
2018 | -64.64% | 4.83% |
2017 | -61.66% | -17.84% |
2016 | -75.05% | 167.47% |
2015 | -28.06% | -172.71% |
2014 | 38.59% | 12.84% |
The current ROE of CytomX Therapeutics, Inc. (CTMX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
8.14%
5-year avg
-48.32%
10-year avg
-43.24%
CytomX Therapeutics, Inc.’s ROE is less than Spero Therapeutics, Inc. (3.36%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Instil Bio, Inc. (-37.44%), greater than NextCure, Inc. (-62.50%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Achilles Therapeutics plc (-54.57%), greater than Nuvation Bio Inc. (-108.68%),
Company | ROE | Market cap |
---|---|---|
3.36% | $63.24M | |
-8.54% | $8.20M | |
-37.44% | $170.65M | |
-62.50% | $33.33M | |
-121.46% | $95.60M | |
-54.57% | $43.57M | |
-108.68% | $942.39M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytomX Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CytomX Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is CytomX Therapeutics, Inc.'s ROE?
How is the ROE calculated for CytomX Therapeutics, Inc. (CTMX)?
What is the highest ROE for CytomX Therapeutics, Inc. (CTMX)?
What is the 3-year average ROE for CytomX Therapeutics, Inc. (CTMX)?
What is the 5-year average ROE for CytomX Therapeutics, Inc. (CTMX)?
How does the current ROE for CytomX Therapeutics, Inc. (CTMX) compare to its historical average?